## UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): September 3, 2013

Protalix BioTherapeutics, Inc. (Exact name of registrant as specified in its charter)

Florida (State or other jurisdiction of incorporation) 001-33357 (Commission File Number) 65-0643773 (IRS Employer Identification No.)

2 Snunit Street
Science Park, POB 455
Carmiel, Israel
(Address of principal executive offices)

(Zip Code)

20100

Registrant's telephone number, including area code +972-4-988-9488 (Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Item 5.02. Departure of Directors or Certain	n Officers; Election of Di	rectors; Appointment of Certa	in Officers; Co	mpensatory A	rrangements of
Certain Officers					

On September 3, 2013, Alfred Akirov resigned as a member of the Board of Directors of Protalix BioTherapeutics, Inc. effective immediately, due to increasing demands from his other business interests out of the country, and other time constraints.

## **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

## PROTALIX BIOTHERAPEUTICS, INC.

Date: September 3, 2013 By: /s/ David Aviezer, Ph.D.

Name: David Aviezer, Ph.D.

Title: President and Chief Executive Officer